Onconetix, Inc. (NASDAQ:ONCO - Get Free Report)'s stock price traded down 24.9% on Friday . The company traded as low as $4.65 and last traded at $4.73. 302,077 shares were traded during mid-day trading, an increase of 193% from the average session volume of 102,989 shares. The stock had previously closed at $6.30.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded shares of Onconetix to a "hold" rating in a report on Saturday.
Read Our Latest Stock Report on ONCO
Onconetix Price Performance
The business's fifty day moving average price is $6.11 and its two-hundred day moving average price is $25.39.
Onconetix (NASDAQ:ONCO - Get Free Report) last released its quarterly earnings results on Thursday, June 12th. The company reported $21.25 earnings per share for the quarter. The firm had revenue of $0.10 million during the quarter.
Institutional Trading of Onconetix
A hedge fund recently bought a new stake in Onconetix stock. Geode Capital Management LLC bought a new position in Onconetix, Inc. (NASDAQ:ONCO - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 55,418 shares of the company's stock, valued at approximately $35,000. Geode Capital Management LLC owned approximately 0.67% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by institutional investors.
About Onconetix
(
Get Free Report)
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Onconetix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Onconetix wasn't on the list.
While Onconetix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
